Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Solvay Seiyaku Submits NDA For SA-001 In Japan
Solvay Seiyaku K K, the Japanese entity of Solvay Pharmaceuticals, has submitted a New Drug Application (NDA) for SA-001, a pancreatic enzyme replacement therapy agent for pancreatic exocrine
Solvay Seiyaku K K, the Japanese entity of Solvay Pharmaceuticals, has submitted a New Drug Application (NDA) for SA-001, a pancreatic enzyme replacement therapy agent for pancreatic exocrine
Teva-KOWA Pharma has signed a definitive agreement to acquire a majority of the outstanding shares of Taisho Pharmaceutical Industries (Taisho). As per the agreement, Teva-KOWA Pharma is expected
Questcor Pharmaceuticals has said that the FDA now considers that the company has provided a complete response to all prior action letters for its supplemental New Drug Application
SemBioSys Genetics (SemBioSys) has provided an update on its progress on plant-produced Apo AI (Milano), in light of the license agreement between Pfizer and The Medicines Company, New
ImmuneRegen BioSciences (ImmuneRegen), a subsidiary of IR Biosciences Holdings, has provided an update on the understanding of the mechanisms underlying the immunostimulatory activity of its development candidate, Homspera.
Community Health Systems’ subsidiary has entered into an affiliation agreement with Rockwood Clinic, with 32 locations across the Inland Northwest region of the State of Washington. The transaction
Applied NeuroSolutions has reached an agreement with Eli Lilly to increase the scope of its drug discovery collaboration. In addition to the financial terms from the original collaboration
Amgen has reported that the US District Court in Boston has entered final judgment and a permanent injunction against Roche prohibiting Roche from infringing Amgen’s patents on recombinant
The Medicines Company has reported the exclusive worldwide licensing of ApoA-I Milano from Pfizer. The company claims that ApoA-I Milano is a naturally occurring variant of a protein
Pfizer Canada has reported that following a priority review, Health Canada has approved Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein)) for children aged six weeks through